<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390530</url>
  </required_header>
  <id_info>
    <org_study_id>2017-8707</org_study_id>
    <nct_id>NCT03390530</nct_id>
  </id_info>
  <brief_title>Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage</brief_title>
  <acronym>IVHT4</acronym>
  <official_title>Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage: Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Westchester Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Morgan Stanley Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Minnesota Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arkansas Children's Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain bleed in premature infants damages the brain and survivors suffer from cerebral palsy&#xD;
      (weakness in the extremities), cognitive deficits, and neurobehavioral disorders. In this&#xD;
      clinical trial, investigators will test whether thyroxine (hormone from thyroid gland)&#xD;
      treatment in premature infants with moderate-to-large brain bleeds show recovery in the brain&#xD;
      structure on MRI evaluation at the time of discharge (44+/-1 weeks) and neurodevelopmental&#xD;
      improvement at 2 years of age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intraventricular hemorrhage (IVH) remains a major complication of prematurely born infants.&#xD;
      Survivors of IVH suffer from cerebral palsy, cognitive deficits and neurobehavioral&#xD;
      disorders. In the proposed study We hypothesize that T4 treatment in preterm (230/7-276/7&#xD;
      weeks) infants with grade II-IV IVH will: a) improve MRI biomarkers, including total&#xD;
      myelinated white matter volume, Kidokoro scoring, functional connectivity between motor brain&#xD;
      regions, and fractional anisotropy in the corpus callosum of preterm infants with grade II-IV&#xD;
      IVH at 36 weeks postmenstrual age, and b) better composite outcome of disability and death.&#xD;
      The composite outcome will be derived by integrating scores for Bayley Scales of Infant and&#xD;
      Toddler Development (BSID-IV) Motor subscale at 22-26 months in survivors and BSID IV value&#xD;
      of 46 assigned to deceased infants. To test these hypotheses, we will perform a randomized&#xD;
      double-blinded placebo-controlled trial to determine the effect of T4 treatment on preterm&#xD;
      infants with grade II-IV IVH. Ten participating neonatal intensive care units will enroll 346&#xD;
      premature infants (230/7-276/7 weeks gestational age. 173 in each arm) with unilateral or&#xD;
      bilateral grade II-IV IVH over a period of 3 years. The treatment will consist of T4&#xD;
      administration (8 µg/kg/day divided into two doses) up to 34 weeks of postmenstrual age,&#xD;
      which will be initiated at 2-5 days of postnatal age in all cases. The infants will undergo&#xD;
      MRI with DTI at 36 weeks and neurobehavioral evaluation at 22-26 months of corrected age. We&#xD;
      have assumed a 7.5 point mean difference (SD=15) in BSID-IV motor subscale between T4 and&#xD;
      placebo groups, an overall mortality rate of 25%, and 5% reduction in mortality for each SD&#xD;
      change in outcome. Based on these, we expect an increase in the induced composite outcome by&#xD;
      ≥5.6 points in T4 treated group compared to placebo controls. The study will conclusively&#xD;
      determine whether the proposed clinical trial of T4 treatment enhances motor outcome and&#xD;
      diminishes composite endpoint of death or disability in preterm infants with grade II-IV IVH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Closed by PI prior to approval&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 18, 2022</start_date>
  <completion_date type="Anticipated">January 18, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded, placebo-controlled, and randomized controlled trial to compare outcomes between thyroxine and placebo treatment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded and randomized</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Death or disability</measure>
    <time_frame>22-26 months of age</time_frame>
    <description>The primary outcome will be a quantitative composite outcome using the BSID-IV Motor score measured at 22-26 months among survivors while incorporating death using a floor value of 46.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BSID-IV Motor subscale</measure>
    <time_frame>22-26 months of age</time_frame>
    <description>Bayley Scales of Infant and Toddler Development (BSID) IV score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSID-IV Cognitive subscale</measure>
    <time_frame>22-26 months of age</time_frame>
    <description>Bayley Scales of Infant and Toddler Development (BSID) IV score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSID-IV Language subscale</measure>
    <time_frame>22-26 months of age</time_frame>
    <description>Bayley Scales of Infant and Toddler Development (BSID) IV score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary composite outcome of death or moderate/severe NDI</measure>
    <time_frame>22-26 months of age</time_frame>
    <description>NDI will be defined as the presence of any of the following: BSID-IV Cognitive &lt; 85, BSID-IV Motor &lt;85, GMFCS ≥ 2 (NICHD, Neonatal Res. Network 2018)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral palsy incidence and severity</measure>
    <time_frame>22-26 months of age</time_frame>
    <description>We will perform neurological examination as in PENUT study and GMFCS scoring to determine cerebral palsy incidence and severity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MRI studies: dMRI measures (fractional anisotropy; radial, axial and mean diffusivity) in the corpus callosum and corticospinal tract</measure>
    <time_frame>44+/-1 weeks of postmenstrual age</time_frame>
    <description>dMRI analyses</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI studies: myelinated and unmyelinated WM brain volume</measure>
    <time_frame>44+/-1 weeks of postmenstrual age</time_frame>
    <description>After visual quality control, initial total brain segmentation for tissue types will be done using T2 weighted images with MANTIS, an in-house method of automated Morphologically Adaptive Neonatal Tissue Segmentation (Alexander, et al. 2017)</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI studies: Kidokoro WM and global scores</measure>
    <time_frame>44+/-1 weeks of postmenstrual age</time_frame>
    <description>Kidokoro WM and global scores as in Kidokoro et al ( Am J Neuroradiol 34, 2208-2214:2013)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Intraventricular Hemorrhage of Prematurity</condition>
  <arm_group>
    <arm_group_label>Thyroxine treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous thyroxine in a dose of 8 µg/kg/day divided into two doses (every 12 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous placebo treatment every 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thyroxine</intervention_name>
    <description>8 µg/kg/day divided into two doses intravenous every 12 hours</description>
    <arm_group_label>Thyroxine treatment</arm_group_label>
    <other_name>Levothyroxine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo treatment</arm_group_label>
    <other_name>Inactive substance in a similarly looking solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  NICU inpatients born between 23-0/7 and 27-6/7 weeks of gestation&#xD;
&#xD;
          -  Postnatal age 2-5days (≥2 d ≤ 5 d)&#xD;
&#xD;
          -  Unilateral or bilateral Grade 3 or 4 IVH&#xD;
&#xD;
          -  Parental consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Major malformations, including surgical, cardiac, cerebral, chromosomal, or genetic&#xD;
             syndromes, identifiable at or before birth;&#xD;
&#xD;
          -  Congenital bacterial infection proven by culture at birth or viral syndrome known&#xD;
             prior to delivery (e.g. chicken pox, rubella, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PRAVEEN BALLABH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praveen Ballabh</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Praveen Ballabh</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Thyroxine</keyword>
  <keyword>Intraventricular hemorrhage</keyword>
  <keyword>MRI with DTI,</keyword>
  <keyword>Neurodevelopmental outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

